Ambry Genetics launches whole genome sequencing test for rare diseases

Go back to Ambry Genetics launches whole genome sequencing test for rare diseases

Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases

October 13, 2026 6:00 AM EDT

New offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challenges

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of... More